Cochlear
COH.ASXHealth Care
Manufacture and sale of Cochlear implant systems.
Market Data
$99.010
+0.0%$6.4B
18.5x
$5.266
4.41%
-0.5%
Latest Earnings
Appendix 4D and Half Year Financial Report
13 February 2026
Cochlear delivered mixed H1 FY26 results with sales revenue flat at $1,176m (+1% reported, -2% constant currency) but underlying net profit declined 9% to $195m due to higher emerging markets mix and slower Nucleus Nexa launch. The company expects a stronger H2 driven by broad Nexa availability and maintains FY26 underlying net profit guidance at the lower end of $435-460m range. Key points: Cochlear implant units grew 6% to 27,016 with Nucleus Nexa System receiving positive reception from professionals; Strong momentum in November/December with ~10% YoY growth in cochlear implant units, 80% comprising new Nexa System; Services revenue increased 2% to $311.6m driven by growth in developed markets
Recent Announcements
Ceasing to be a substantial holder
The Bank of New York Mellon Corporation (BNY) ceased to be a substantial holder.
Ceasing to be a substantial holder
AustralianSuper Pty Ltd ceased to be a substantial holder.
Trading update and reduction to FY26 earnings guidance
Cochlear Limited has reduced its FY26 underlying net profit guidance to $290-330 million (from $435-460 million) due to softer-than-expected trading in developed market cochlear implants, Middle East conflict uncertainty, lower gross margins, cost restructuring expenses, and foreign exchange headwinds. Second half sales growth is now expected to be 2-6% in constant currency, though the company remains confident in its long-term growth strategy and innovation pipeline.
Becoming a substantial holder
The Bank of New York Mellon Corporation (BNY) became a substantial holder.
Ceasing to be a substantial holder
The Bank of New York Mellon Corporation (BNY) ceased to be a substantial holder.
Becoming a substantial holder
The Bank of New York Mellon Corporation (BNY) became a substantial holder.
Ceasing to be a substantial holder
Pinnacle Investment Management Group Limited ceased to be a substantial holder (20%).
Appendix 4D and Half Year Financial Report
Cochlear delivered mixed H1 FY26 results with sales revenue flat at $1,176m (+1% reported, -2% constant currency) but underlying net profit declined 9% to $195m due to higher emerging markets mix and slower Nucleus Nexa launch. The company expects a stronger H2 driven by broad Nexa availability and maintains FY26 underlying net profit guidance at the lower end of $435-460m range. Key points: Cochlear implant units grew 6% to 27,016 with Nucleus Nexa System receiving positive reception from professionals; Strong momentum in November/December with ~10% YoY growth in cochlear implant units, 80% comprising new Nexa System; Services revenue increased 2% to $311.6m driven by growth in developed markets
Earnings Release - 13 February 2026
Upcoming earnings release expected 13 February 2026 (from Yahoo Finance (confirmed))
Get real-time alerts for COH
Receive AI-powered earnings summaries and instant notifications when Cochlear releases results.
Register Free